Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
  Top » Catalog » Books » Biology » Biology - General » Drug-Resistant Tuberculosis: Causes, Diagnosis and Treatments Chapters » My Account  |  Cart Contents  |  Checkout   
Quick Find
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Quantum Kinetics: Duration of Basic Elementary Processes
Shopping Cart more
0 items
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Notifications more
NotificationsNotify me of updates to Tuberculosis — The Development of New MDR-TB Drugs
Tell A Friend
Tell someone you know about this product.
Tuberculosis — The Development of New MDR-TB Drugs $100.00
Authors:  Jarmila Vinšová and Martin Krátký
The aim of this review is to outline the recent advances in the development of new
multidrug-resistant tuberculosis (MDR-TB) drugs. The emergence of resistance to
antituberculosis drugs, particularly of MDR-TB and more recently XDR-TB, has become
a major public health problem. The current treatment regimen has several disadvantages,
i.e. long treatment period (DOTS takes minimum 6 months) during which tubercle bacilli
mutant becomes resistant to one or more drugs; side effects of the used drugs; coinfection
of HIV/AIDS. The emergence of MDR-TB has made many currently available
anti-TB drugs ineffective. Sleeping latent forms of mutant bacilli resistant to common
anti-TB drugs create the risk of epidemic for the new generation. Therefore, there is an
urgent need to identify new drug targets and to find novel chemical structures active
especially against MDR-TB.
In general, drug resistance mechanisms in Mycobacterium tuberculosis are caused
by mutations in chromosomal genes. It includes target modifications, barrier mechanism,
inactivation or activation of enzymes, mutation in the genes such as inhA, rpoB, rpsL,
rrs, emrB and gyrA, responsible for INH, RIF, STM, EMB and quinolone resistances.
Some novel targets as an essential cell division protein (FtsZ), ATP-synthase target,
isocitrate lyase, targeting P450 enzymes, etc., are presented. The research of novel MDR
potential drugs follows six main strategies: a) structure modification of known
compounds (INH, RIF, PZA, ETH, EMB, quinolones); b) new leads with novel
mechanism of action (linezolid, TMC207, PA-824, OPC-67683, BM212, SQ109,
FAS20013, LL-3858); c) novel drug targets, i.e. cell wall biosynthesis (mycolic acid
synthesis, protein synthesis, arabinogalactan and peptidoglycan biosynthesis inhibitors)
or other novel targets like enzymes; d) investigation of “non-antituberculous” drugs; e) testing of newly prepared synthetic compounds without known mechanism of action; f)
screening of natural products, determination and isolation of active compounds. 

Available Options:
This Item Is Currently Unavailable.
Special Focus Titles
01.Multicultural and Citizenship Awareness through Language: Cross Thematic Practices in Language Pedagogy
02.The Brainstem and Behavior
03.Sustainable Development: The Context of Use of Indigenous Plants for Local Economic Growth
04.Cancer versus Nutraceuticals
05.Fundamentals of Fuel Injection and Emission in Two-Stroke Engines
06.Free to Love: Schema Therapy for Christians
07.Textiles: Advances in Research and Applications
08.Cheese Production, Consumption and Health Benefits
09.Education in Lesotho: Prospects and Challenges
10.Work-Life Balance in the 21st Century: Perspectives, Practices, and Challenges
11.Electrical Measurements: Introduction, Concepts and Applications
12.Potassium Channels in Health and Disease

Nova Science Publishers
© Copyright 2004 - 2018

Tuberculosis — The Development of New MDR-TB Drugs